Lifecore Biomedical, Inc. De
LFCR Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$6.44
KIRA · Stoqly’s AI analyst, in plain words
- Lifecore Biomedical, Inc. De had $129M of revenue in fiscal 2025, up 0.5% on the year before. Over five years, revenue changed −4.2% a year on average.
- Its operating margin was −13.4%, down 6.5 pts: of every 100 in sales, about −13 is left after running the business.
- Lifecore Biomedical, Inc. De lost $38.7M in fiscal 2025.
- Free cash flow was −$13.6M in fiscal 2025, −10.6% of revenue.
- Lifecore Biomedical, Inc. De owes $128M more than it holds in cash.
Market cap
$241M
P/E
—
Revenue
$129M
Net income
−$38.7M
Free cash flow
−$13.6M
Operating margin
−13.4%
Lifecore Biomedical, Inc. De in 30 seconds · fiscal 2025
Are sales growing?
+0.5%
Only a little. Sales grew 0.5% last year.
Does it make a profit?
−30.0%
No. It lost money last year.
Does profit turn into cash?
−10.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Lifecore Biomedical, Inc. De does
No business description yet.
- Fiscal year ends
- May 25, 2025
- Latest annual report
- 10-KT · Mar 16, 2026
- Legal name
- LIFECORE BIOMEDICAL, INC. \DE\
- CIK
- 0001005286
Lifecore Biomedical, Inc. De · LFCR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $101M | $111M | $103M | $128M | $129M |
| Revenue growth | −37.0% | 10.3% | −7.2% | 24.2% | 0.5% |
| Gross margin | 38.6% | 35.1% | 27.1% | 32.6% | 31.3% |
| Operating margin | −8.7% | −10.6% | −21.1% | −6.9% | −13.4% |
| Net income | −$32.3M | −$117M | −$99.6M | $12.0M | −$38.7M |
| Net margin | −32.0% | −104.9% | −96.4% | 9.4% | −30.0% |
| Diluted EPS | −$1.10 | −$3.97 | −$3.32 | $0.33 | −$1.27 |
| Cash | |||||
| Cash from operations | $16.5M | −$22.6M | −$17.4M | $0.3M | −$0.2M |
| Capital expenditure | $19.3M | $26.2M | — | $18.4M | $13.4M |
| Free cash flow | −$2.8M | −$48.8M | — | −$18.1M | −$13.6M |
| FCF margin | −2.8% | −43.9% | — | −14.1% | −10.6% |
| Share count change | 0.5% | 0.6% | 1.7% | 22.4% | −5.0% |
| Debt and strength | |||||
| Cash and short-term investments | $0.8M | $1.0M | $19.1M | $8.5M | $8.3M |
| Debt incl. finance leases | $168M | $101M | $88.2M | $128M | $136M |
| Shareholders' equity | $202M | $87.8M | −$4.2M | $11.3M | $1.3M |
| Net debt / EBITDA | 15.2x | 16.0x | — | — | — |
| Current ratio | 1.4x | 0.7x | 2.4x | 2.1x | 2.8x |
| Interest coverage | −1.0x | −0.8x | −1.2x | −0.5x | −0.8x |
| Returns and quality | |||||
| Return on capital | −1.9% | −5.0% | −28.0% | −6.8% | −11.0% |
| Return on equity | −15.0% | −80.6% | −238.2% | 339.1% | −612.1% |
| Return on tangible equity | −17.9% | −160.2% | — | — | — |
| Piotroski F-score | 6 | 2 | 5 | 5 | 4 |
| Altman Z'' | 1.4 | −2.2 | −1.5 | −1.2 | −1.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Lifecore Biomedical, Inc. De · LFCR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.44 a share, the company is worth $241M.
Source: SEC EDGAR XBRL filings (CIK 0001005286). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.